Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DHR 
Danaher Corporation (DHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: DHR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $243.2
1 Year Target Price $243.2
| 19 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.92% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 144.97B USD | Price to earnings Ratio 42.89 | 1Y Target Price 243.2 |
Price to earnings Ratio 42.89 | 1Y Target Price 243.2 | ||
Volume (30-day avg) 26 | Beta 0.8 | 52 Weeks Range 170.43 - 277.73 | Updated Date 10/13/2025 |
52 Weeks Range 170.43 - 277.73 | Updated Date 10/13/2025 | ||
Dividends yield (FY) 0.58% | Basic EPS (TTM) 4.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-21 | When Before Market | Estimate 1.72 | Actual - |
Profitability
Profit Margin 14.21% | Operating Margin (TTM) 20.12% |
Management Effectiveness
Return on Assets (TTM) 4.01% | Return on Equity (TTM) 6.68% |
Valuation
Trailing PE 42.89 | Forward PE 24.39 | Enterprise Value 165005130924 | Price to Sales(TTM) 6.04 |
Enterprise Value 165005130924 | Price to Sales(TTM) 6.04 | ||
Enterprise Value to Revenue 6.87 | Enterprise Value to EBITDA 24.43 | Shares Outstanding 716051590 | Shares Floating 637121223 |
Shares Outstanding 716051590 | Shares Floating 637121223 | ||
Percent Insiders 11.05 | Percent Institutions 82.79 |
Upturn AI SWOT
Danaher Corporation
Company Overview
History and Background
Danaher Corporation was founded in 1969 as DMG, Inc. Initially a real estate investment trust, it later transitioned into manufacturing and rebranded as Danaher in 1984. Through strategic acquisitions and a focus on operational efficiency ('The Danaher Business System'), it has grown into a global science and technology innovator.
Core Business Areas
- Life Sciences: Provides a broad range of research tools used to analyze fundamental biological components, including genomics, proteomics, cell biology, and microbiology. Key applications include drug discovery, diagnostics, and biomanufacturing. Focus is on innovation in Genomics, Proteomics, and Cell Analysis
- Diagnostics: Offers diagnostic instruments, reagents, and consumables used to analyze blood, tissue, and other bodily fluids to detect diseases, monitor patient health, and guide treatment decisions. Instruments used for clinical testing in hospitals and labs.
- Environmental & Applied Solutions: Provides products and services that help protect the environment and ensure product safety. Focus is on water quality, product identification, and packaging integrity. The company provides instruments, consumables and software to help its customers solve critical environmental and safety challenges.
Leadership and Structure
Danaher is led by CEO Rainer M. Blair. The company operates under a decentralized structure, with individual operating companies having significant autonomy within the framework of the Danaher Business System (DBS).
Top Products and Market Share
Key Offerings
- Cytiva Bioprocessing: Provides technologies and services for biopharmaceutical manufacturing, including cell culture, purification, and analysis. Dominant in bioprocessing. Competitors: Thermo Fisher Scientific (TMO), Sartorius AG (SRT.F). Market data is not publicly shared, but has one of the largest market shares in the industry.
- Beckman Coulter Diagnostics: Offers a wide range of clinical diagnostic instruments and reagents used in hospitals and laboratories. Competitors include Roche (ROG.SW), Abbott Laboratories (ABT), and Siemens Healthineers (SHL.DE). Market data is not publicly shared, but has one of the largest market shares in the industry.
- Hach Water Quality: Provides water analysis instruments and reagents for municipal, industrial, and environmental applications. Competitors: Xylem (XYL), Thermo Fisher Scientific (TMO), and Endress+Hauser. Market data is not publicly shared, but has one of the largest market shares in the industry.
Market Dynamics
Industry Overview
The life sciences, diagnostics, and environmental & applied solutions industries are experiencing strong growth, driven by increasing healthcare spending, aging populations, and growing awareness of environmental issues. Technological advancements, such as genomics and automation, are also key drivers.
Positioning
Danaher is a leading player in these industries, known for its strong brand reputation, innovative products, and efficient operations. The Danaher Business System provides a competitive advantage by driving continuous improvement and operational excellence.
Total Addressable Market (TAM)
The combined TAM for Danaher's key segments is estimated to be hundreds of billions of USD. Danaher holds a significant position and continues to penetrate the market with both innovation and acquisition.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Danaher Business System (DBS)
- Diversified business portfolio
- History of successful acquisitions
- Strong cash flow generation
- Global presence
Weaknesses
- High reliance on acquisitions for growth
- Exposure to cyclical industries
- Integration risks associated with acquisitions
Opportunities
- Growing demand for life sciences, diagnostics, and environmental solutions
- Expansion into emerging markets
- Technological advancements (e.g., genomics, automation)
- Strategic acquisitions to expand product portfolio and market share
Threats
- Economic downturns
- Increased competition
- Regulatory changes
- Disruptive technologies
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Roche Holding AG (RHHBY)
- Siemens Healthineers (SHL.DE)
Competitive Landscape
Danaher's competitive advantages include its strong brand, the Danaher Business System, and its diversified business portfolio. However, it faces competition from other large players with established market positions.
Major Acquisitions
Aldevron
- Year: 2021
- Acquisition Price (USD millions): 9600
- Strategic Rationale: Expanded Danaher's bioprocessing capabilities and position in the rapidly growing cell and gene therapy market.
Growth Trajectory and Initiatives
Historical Growth: Danaher has achieved strong growth through a combination of organic growth and acquisitions.
Future Projections: Analyst estimates suggest continued growth in the life sciences, diagnostics, and environmental & applied solutions markets. Danaher is expected to benefit from these trends.
Recent Initiatives: Recent initiatives include strategic acquisitions, investments in research and development, and expansion into new markets.
Summary
Danaher is a strong company with a diversified portfolio of businesses in attractive industries. Its disciplined acquisition strategy, combined with the Danaher Business System, has driven consistent growth and profitability. While reliant on acquisitions and subject to market cyclicality, Danaher is well-positioned for continued success in the long term. Continued focus on integrating acquired companies and navigating market shifts will be critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Reports
- Financial News Sources
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Danaher Corporation
Exchange NYSE | Headquaters Washington, DC, United States | ||
IPO Launch date 1979-01-05 | President, CEO & Director Mr. Rainer M. Blair | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 61000 | Website https://www.danaher.com |
Full time employees 61000 | Website https://www.danaher.com | ||
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.